Wedemeyer, H. Et Al. 2019. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. LANCET INFECTIOUS DISEASES , vol.19, no.3 , 275-286.

Wedemeyer, H., Yurdaydin, C., Hardtke, S., Caruntu, F. A., Curescu, M. G., YALÇIN, K., ... AKARCA, U. S.(2019). Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. LANCET INFECTIOUS DISEASES , vol.19, no.3, 275-286.

Wedemeyer, Heiner Et Al. "Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial," LANCET INFECTIOUS DISEASES , vol.19, no.3, 275-286, 2019

Wedemeyer, Heiner Et Al. "Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial." LANCET INFECTIOUS DISEASES , vol.19, no.3, pp.275-286, 2019

Wedemeyer, H. Et Al. (2019) . "Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial." LANCET INFECTIOUS DISEASES , vol.19, no.3, pp.275-286.

@article{article, author={Heiner Wedemeyer Et Al. }, title={Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial}, journal={LANCET INFECTIOUS DISEASES}, year=2019, pages={275-286} }